Home » Newsletters » BioWorld

BioWorld

May 3, 2010

View Archived Issues

New Study Links Autophagy to Metabolic Quirks in Tumor Cells

BIO in Chicago: BioWorld Waxes Nostalgic, Biotech Perseveres

Despite Last-Minute Jitters, Pozen's Vimovo Approved

Off-Label Promotion: Filling an Unmet Need or Boosting Profit?

End of Unapproved Pancreatic Enzymes Ensures Safety: CFF

Protox's $75M Kissei Deal May Set Stage for Larger Alliances

Stock Movers

Earnings Roundup

Other News To Note

Clinic Roundup

Financings Roundup

Bench Press

Provenge Nod Bodes Well, but No Free Pass for Cancer Vaccines

Dendreon Corp. made history last week by securing approval for Provenge (sipuleucel-T), the first therapeutic cancer vaccine ever cleared by the FDA. (BioWorld Today) Read More

NeurogesX Pulls Down $40M Via Qutenza Deal with Cowen